免费电话：400-668-6834 | 技术支持：400-168-6834 | 邮箱：info@selleck.cn

Alpelisib (BYL719)

目录号：S2814 中文名称：阿培利司

仅限科研使用

Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

CAS: 1217486-61-7

规格	价格	库存
10mM (1mL in DMSO)	RMB 876.4	现货
5mg	RMB 728.96	现货
10mg	RMB 1204.67	现货
100mg	RMB 5463.3	现货
大包装	有超大折扣

今日订购，明日送达全国免运费分装免费分装成小规格产品（单支最小为1mg）如1支10mg产品可分装为10支1mg产品全国免费电话：400-668-6834 \| Email：info@selleck.cn

客户使用Selleck生产的Alpelisib (BYL719)发表文献153篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

靶点

PI3Kα ^[1]
(Cell-free assay)

5 nM

体外研究

BYL719抑制含有PIK3CA突变体的乳腺癌细胞系的增殖，与PI3K/Akt通路各种下游信号组分的抑制相关。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Detroit562	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSwMlEuOTByIN88US=>	NGnYUnI4OiCq	MYPJR\|UxRTFwMUCg{txO	Mli4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUC1OFkoRjJ3NUWwOVQ6RC:jPh?=
SNU-1076	NIS5OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV6wMlEuOTByIN88US=>	MYe3NkBp	M2HRNWlEPTB;Nj64NkDPxE1?	NHHHZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SNU-1066	NV[1O41oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrnNE4yNTFyMDFOwG0>	MVG3NkBp	MXvJR\|UxRTFwMUOg{txO	MlGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUC1OFkoRjJ3NUWwOVQ6RC:jPh?=
FaDu	M3fn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M361XFAvOS1zMECg{txO	MoniO\|IhcA>?	NUDnfm5RUUN3ME2xPU43PiEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3MEW0PUc,OjV3NUC1OFk9N2F-
SNU1041	NGn2VlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHWNE4yNTFyMDFOwG0>	M3rMPVczKGh?	NH3N[41KSzVyPUKwMlY2KM7:TR?=	NE\RSVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SCC25	MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjSOnllOC5zLUGwNEDPxE1?	M4\r[lczKGh?	M1LmPWlEPTB;NEmuN\|Ah\|ryP	MlzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUC1OFkoRjJ3NUWwOVQ6RC:jPh?=
BON-1	Mn3LSpVv[3Srb36gRZN{[Xl?	MXGxM\|ExKM7:TR?=	MYO0JIg>	NInkeGVqdmirYnn0d{BRUTONIDjBT3QhW2W{M{C4LUBidmRibWTPVmMyNzJiYXP0bZZqfGmncx?=	NYXrcYMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
QGP-1	NVHGOWdQTnWwY4Tpc44hSXO\|YYm=	Mkf6NU8yOCEQvF2=	MXm0JIg>	MlnVbY5pcWKrdIOgVGk{UyBqQVvUJHNmejNyODmgZY5lKG2WT2LDNU8zKGGldHn2bZRq\XN?	M33veVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK2NlkzLz5{NUCyOlI6OjxxYU6=
MG-63	M{nNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3XieGlEPTB;NjFOwG3wxIxiSVO5NF0zPCEQvF2=	M2PvNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[xO\|kxLz5{NEm2NVc6ODxxYU6=
HOS	NFfVe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXPJR\|UxRTF3IN88Ug+9lCCLQ{mwQVQzKM7:TR?=	NYLKeVFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
MOS-J	NHy5UmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUXjOIpNUUN3ME2xNEDPxE4xvJygTWM6OD1\|NjFOwG0>	NX\UO5pwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
POS-1	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml3OTWM2OD16IN88Ug+9lCCLQ{mwQVM3KM7:TR?=	NUDZc4RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
92.1	MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4K4VVUxOC1{MECwJI5O	NVHTXGJMPSCm	MWDpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd\|KTD1dEB1dyBzIN88US=>	MljLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NkO1OFAoRjJ2NU[zOVQxRC:jPh?=
Mel270	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj2dI42ODBvMkCwNEBvVQ>?	MXW1JIQ>	NX3CSYN[cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1?	NX3idHcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM2PDBpPkK0OVY{PTRyPD;hQi=>
Omm1.3	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYe1NFAuOjByMDDuUS=>	NYizRWhVPSCm	MWHpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd\|KTD1dEB1dyBzIN88US=>	NF3hdYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N\|U1OCd-MkS1OlM2PDB:L3G+
Omm1	NHXTWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTpTmI2ODBvMkCwNEBvVQ>?	NVHSSZI6PSCm	M3nmRolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO	NHLk[3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N\|U1OCd-MkS1OlM2PDB:L3G+
C918	M2\MPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfXbZVpPTByLUKwNFAhdk1?	MmLQOUBl	MWLpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd\|KTD1dEB1dyBzIN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4M{W0NEc,OjR3NkO1OFA9N2F-
Mel290	M4\UO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7NS282ODBvMkCwNEBvVQ>?	M3PzWFUh\A>?	NXHyXoZzcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1?	M3vMXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NU[zOVQxLz5{NEW2N\|U1ODxxYU6=
OPM2	NUXTT4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rpWlAvPS1{LkWg{txO	NVvuRpcxPDhiaB?=	NVewW\|NDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
OPM1	NYnvXFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVm3elJHOC53LUKuOUDPxE1?	NFn2fZI1QCCq	M3\5SYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
U266	M1jGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDnNWMxNjVvMj61JO69VQ>?	NY\DcW57PDhiaB?=	NH;WWm1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NX3i[oJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFUyOjFpPkK0OFA2OTJzPD;hQi=>
MM1R	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH65fpoxNjVvMj61JO69VQ>?	NV;zRXc6PDhiaB?=	NWDoZm97cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	Ml6yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
MM1S	NXPoOoxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlP3NE42NTJwNTFOwG0>	NHy0emY1QCCq	MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NGq3cpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVEzOSd-MkS0NFUyOjF:L3G+
H929	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYWwMlUuOi53IN88US=>	NF;zelg1QCCq	M1yyPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NVfY[WliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NFUyOjFpPkK0OFA2OTJzPD;hQi=>
RPMI	MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUWwMlUuOi53IN88US=>	MmHBOFghcA>?	NWC5N2dCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MljrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
SKBR3	NHzKZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfaVIc{OyEQvF2=	NGj2OZE2KGR?	MUDpcohq[mm2czCzOg+9jSClZXzsJIdzd3e2aB?=	Mm\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ\|OUG4O\|k4RC:jPh?=
MDA453	NYnn[m5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF61O3g{OyEQvF2=	M3voUVUh\A>?	NH:4cXRqdmirYnn0d{A{QO,:hTDj[YxtKGe{b4f0bC=>	M4H6T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUG4O\|k4Lz5{M{mxPFc6PzxxYU6=
EFM192A	NGXD[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7aN\|Mh\|ryP	NIrHfYg2KGR?	MUfpcohq[mm2czCyO-+9jSClZXzsJIdzd3e2aB?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
AU565	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWS3SWd7OzNizszN	NUmwT5J[PSCm	NWXVOppJcW6qaXLpeJMhOjcxvJWgZ4VtdCCpcn;3eIg>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
MDA361	NX7xc\|ZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfTN\|Mh\|ryP	M4HiT\|Uh\A>?	NFvxSGtqdmirYnn0d{A1PO,:hTDj[YxtKGe{b4f0bC=>	NVLGeFNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
BT474	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjRN\|Mh\|ryP	MV61JIQ>	MV\pcohq[mm2czCxOw+9jSClZXzsJIdzd3e2aB?=	NEXsVIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
HCC202	M1r1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;BUpc{OyEQvF2=	MnvBOUBl	M2jGeYlvcGmkaYTzJFIx97zHIHPlcIwh\3Kxd4To	MlHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ\|OUG4O\|k4RC:jPh?=
KPL4	M3nLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjqZmU{OyEQvF2=	NFvDSm02KGR?	MWrpcohq[mm2czC1PQ+9jSClZXzsJIdzd3e2aB?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
NCL-N87	NUTIclRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml2xN\|Mh\|ryP	NHL0epk2KGR?	MoexbY5pcWKrdIOgN\|HwxIViY3XscEBoem:5dHi=	M{TsT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUG4O\|k4Lz5{M{mxPFc6PzxxYU6=
UACC812	M{DqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUSzN{DPxE1?	MY[1JIQ>	NXGwdod4cW6qaXLpeJMhOjgxvJWgZ4VtdCCpcn;3eIg>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
HCC2218	M{m1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXBfpNoOzNizszN	MkC1OUBl	NFuwT\|NqdmirYnn0d{AyPe,:hTDj[YxtKGe{b4f0bC=>	NGi0O4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
HCC1569	M{m3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjBN\|Mh\|ryP	MkXGOUBl	MYfpcohq[mm2czC189yGKGOnbHyg[5Jwf3Sq	M3PpXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUG4O\|k4Lz5{M{mxPFc6PzxxYU6=
OE19	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUSzN{DPxE1?	MUG1JIQ>	M4LteYlvcGmkaYTzJFI{97zHIHPlcIwh\3Kxd4To	M3TXXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUG4O\|k4Lz5{M{mxPFc6PzxxYU6=
OE33	MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXuN\|Mh\|ryP	NXTxZXVoPSCm	NYTIWVFwcW6qaXLpeJMhOjQxvJWgZ4VtdCCpcn;3eIg>	MnjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ\|OUG4O\|k4RC:jPh?=
JIMT1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnDN\|Mh\|ryP	MlX4OUBl	MnO1bY5pcWKrdIOgPg+9jSClZXzsJIdzd3e2aB?=	M2rRblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUG4O\|k4Lz5{M{mxPFc6PzxxYU6=
HCC1954	M1nweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vFRVM{KM7:TR?=	NHfOOFk2KGR?	MXnpcohq[mm2czCyPg+9jSClZXzsJIdzd3e2aB?=	M33pVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUG4O\|k4Lz5{M{mxPFc6PzxxYU6=
NUGC4	MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\SN\|Mh\|ryP	NUXLeGtzPSCm	MlPtbY5pcWKrdIOgNVTwxIViY3XscEBoem:5dHi=	NFnTSWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
ZR-75-30	NUfSSZh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWzN{DPxE1?	NWCyN\|lmPSCm	MYLpcohq[mm2czCtNVXwxIViY3XscEBoem:5dHi=	Ml\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ\|OUG4O\|k4RC:jPh?=
Rat1	M1ezOnAyOTCjbIDoZUBqdmirYnn0bY9vKGG\|c3H5			NFTDNJZKSzVyIE2gNE4xPzRizszN	NYTKWY5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlQyQDlpPkK2NVY1OTh7PD;hQi=>
Rat1	MYDQTVNM[WyyaHGgbY5pcWKrdHnvckBie3OjeR?=			NFjvPY1KSzVyIE2gNE4xPzRizszN	MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[1NFQoRjJ4MkC2OVA1RC:jPh?=
Rat1	MUHQNVEx[WyyaHGgbY5pcWKrdHnvckBie3OjeR?=			MkLKTWM2OCB;IECuNFc1KM7:TR?=	MnOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5Mk[wN\|QoRjJ\|N{K2NFM1RC:jPh?=
Rat1	M1X2cXAyOTCmZXz0ZUBqdmirYnn0bY9vKGG\|c3H5			MmT5TWM2OCB;IEGuNkDPxE1?	NVzxNppxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlQyQDlpPkK2NVY1OTh7PD;hQi=>
Rat1	NYjwN3puWEl\|S3fhcY1iKGmwaHnibZRqd25iYYPzZZk>			MXrJR\|UxKD1iMT6yJO69VQ>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJyNkWwOEc,OjZ{ME[1NFQ9N2F-
Rat1	M2TY[HAyOTCmZXz0ZUBqdmirYnn0bY9vKGG\|c3H5			NVf6OGNMUUN3MDC9JFEvOiEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{NkCzOEc,OjN5Mk[wN\|Q9N2F-
Rat1	M2DvSnAyOTCkZYThJIlvcGmkaYTpc44h[XO\|YYm=			MXzJR\|UxKD1iMj6yJO69VQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4NEG4PUc,OjZzNkSxPFk9N2F-
Rat1	MWDQTVNM[mW2YTDpcohq[mm2aX;uJIF{e2G7			M1vyRmlEPTBiPTCyMlIh\|ryP	M4T0OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkC2OVA1Lz5{NkKwOlUxPDxxYU6=
Rat1	M3fKfnAyOTCjbIDoZUBqdmirYnn0bY9vKGG\|c3H5			NEDvTHNKSzVyIE2gNk4zKM7:TR?=	NYD5[IVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NlYxOzRpPkKzO\|I3ODN2PD;hQi=>

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-AKT(S473) / p-AKT(T308) p100β / p110α / p85 / p-ERBB3(Y1289) p-HER2 / IGF-1R pS6 (Ser235-236) PIM1 / PIM2 / PIM3 / p-PRAS40 / p-RPS6 / p-BAD	25544637 27048245 27604488
Growth inhibition assay	Cell viability	27602501
Immunofluorescence	LC3	26637440

体内研究

BYL719(>270 mg/d)在PIK3CA突变体异种移植啮齿动物模型中表现出统计学显著的剂量依赖性抗肿瘤效能。BYL719具有低清除率，半衰期为8.5小时，并且它的作用在30mg/d 和450mg/d之间剂量成比例的增加，在人的Cmax 和AUC中显示出低的个体差异。BYL719(270mg/d)首次表现出临床疗效的迹象，包括在ER+乳腺癌患者中证实的部分响应，以及17个患者中8个实现了显著的PET响应(PMR)和/或肿瘤治愈。^[1]

参考文献	[1] Dejan Juric, et al. 2012, AACR 103rd Annual Meeting. Abst CT-01.

溶解度（25°C）

体外


体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O 点击购买： PEG300 Tween 80	4.4 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量	441.47
化学式	C₁₉H₂₂F₃N₅O₂S
CAS号	1217486-61-7
储存条件	3年	-20°C	粉状
储存条件	2年	-80°C	溶于溶剂

Download Alpelisib (BYL719) SDF

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

临床试验信息

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05230810	Not yet recruiting	Drug: Alpelisib\|Drug: Tucatinib\|Drug: Fulvestrant	HER2-positive Metastatic Breast Cancer	Criterium Inc.\|Novartis\|Seagen Inc.	June 30 2022	Phase 1\|Phase 2
NCT05143229	Recruiting	Drug: Alpelisib\|Drug: Sacituzumab govitecan	Breast Cancer	University of Kansas Medical Center\|Novartis Pharmaceuticals\|Gilead Sciences	March 28 2022	Phase 1
NCT05195892	Recruiting	Drug: Treatment A\|Drug: Treatment B\|Drug: Treatment C	Healthy Volunteers	Novartis Pharmaceuticals\|Novartis	February 3 2022	Phase 1
NCT04980833	Recruiting	Drug: Alpelisib	PIK3CA-related Overgrowth Spectrum (PROS)	Novartis Pharmaceuticals\|Novartis	January 27 2022	Phase 2
NCT04997902	Recruiting	Drug: Tipifarnib\|Drug: Alpelisib	HNSCC	Kura Oncology Inc.	December 7 2021	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):